FoldRx
FDA accepts Pfizer rare disease drug for review
February 15, 2012Sales and Marketing EMA, FDA, FoldRx, Pfizer, tafamidis meglumine
The FDA has accepted for review Pfizer’s new drug to treat a rare neurodegenerative disease. Pfizer is seeking a licence …
Pfizer acquires ‘protein misfolding’ specialist
September 2, 2010Research and Development FoldRx, Pfizer, cystic fibrosis
Pfizer has bolstered its presence in rare and orphan diseases with the acquisition of FoldRx, a US drug discovery firm …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
